| 张新磊,陈 晨,徐 兢,张文玉,焦东东,朱广健.缬沙坦氢氯噻嗪对高血压合并心力衰竭患者AngⅡ、NT-ProBNP及CTGF的作用分析[J].,2021,(2):269-273 |
| 缬沙坦氢氯噻嗪对高血压合并心力衰竭患者AngⅡ、NT-ProBNP及CTGF的作用分析 |
| Analysis of Valsartan Hydrochlorothiazide in Patients with Hypertension with Heart Failure Ang Ⅱ, the Action of the NT - ProBNP and CTGF |
| 投稿时间：2020-06-06 修订日期：2020-06-30 |
| DOI：10.13241/j.cnki.pmb.2021.02.015 |
| 中文关键词: 缬沙坦氢氯噻嗪 高血压合并心力衰竭 血管紧张素Ⅱ N端前脑钠肽 结缔组织生长因子 |
| 英文关键词: Valsartan hydrochlorothiazide Hypertension complicated with heart failure Angiotensin Ⅱ N-terminal forebrain natriuretic peptide Connective tissue growth factor |
| 基金项目:江苏省自然科学基金项目(K20054128) |
|
| 摘要点击次数: 1075 |
| 全文下载次数: 675 |
| 中文摘要: |
| 摘要 目的：探讨缬沙坦氢氯噻嗪对高血压合并心力衰竭患者血管紧张素Ⅱ（AngⅡ）、氨基末端脑钠尿肽前体（NT-ProBNP）及结缔组织生长因子（CTGF）的作用。方法：选择2016年3月到2019年3月我院收治的高血压合并心力衰竭患者113例进行研究，以随机数表法分为观察组（n=57）和对照组（n=56）。对照组给予贝那普利治疗，观察组在对照组的基础上采用缬沙坦氢氯噻嗪治疗。比较两组患者的临床疗效、AngⅡ、NT-ProBNP及CTGF、左心室射血分数（LVEF）、左心室收缩末期内径（LVESd）、左心室舒张末期内径（LVEDd）、收缩压（SBP）、舒张压（DBP）水平变化情况及并发症发生情况。结果：治疗后，两组总有效率分别为92.98%、 73.21%，差异显著；治疗前，两组AngⅡ、NT-ProBNP及CTGF水平无显著差异（P>0.05）；治疗后，两组AngⅡ、NT-ProBNP及CTGF水平均显著改善，且观察组均低于对照组（P<0.05）；治疗前，两组心功能水平无显著差异（P>0.05）；治疗后，两组心功能水平均显著改善，且观察组LVEF高于对照组，LVESd、LVEDd低于对照组（P<0.05）；治疗前，两组血压水平无显著差异（P>0.05）；治疗后，两组血压水平均显著改善，且观察组SBP、DBP水平显著低于对照组，差异显著（P<0.05）；两组并发症总发生率分别为7.02%、10.71%，差异无显著差异（P>0.05）。结论：在高血压合并心力衰竭患者中应用缬沙坦氢氯噻嗪辅助治疗效果显著，可有效改善患者心功能、AngⅡ、NT-ProBNP及CTGF水平。 |
| 英文摘要: |
| ABSTRACT Objective: To study Analysis of valsartan hydrochlorothiazide in patients with hypertension with heart failure Angiotensin Ⅱ (Ang Ⅱ) and amino terminal brain natriuretic peptide precursor (NT - ProBNP) and connective tissue growth factor (CTGF). Methods: 113 patients ofHypertension complicated with heart failurewhoreceived therapy fromMarch 2016 to March 2019wereselected as research objects. The control group was treated with Benazepril, while the observation group was treated withValsartan hydrochlorothiazide. Then clinical curative effect, Ang Ⅱ, NT - ProBNP and CTGF, left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESd), left ventricular end-diastolic diameter (LVEDd), systolic blood pressure (SBP), diastolic blood pressure (DBP) level changes and complicationswere compared. Results: After treatment, the total effective rates of the two groups were 92.98% and 73.21%, respectively, with significant differences. Before the treatment, two groups of Ang Ⅱ, NT - ProBNP and CTGF levels had no significant difference (P>0.05); After treatment, two groups of Ang Ⅱ, NT - ProBNP and CTGF levels were significantly improved, and the observation group were lower than control group (P<0.05); Before treatment, there was no significant difference in cardiac function between the two groups (P>0.05). After treatment, cardiac function levels in both groups were significantly improved, and LVEF and LVESd in the observation group were higher than those in the control group, while LVESd and LVEDd were lower than those in the control group (P<0.05). Before treatment, there was no significant difference in blood pressure between the two groups (P>0.05). After treatment, blood pressure levels in both groups were significantly improved, and SBP and DBP levels in the observation group were significantly lower than those in the control group (P<0.05). The total incidence of complications in the two groups was 7.02% and 10.71%, respectively, with no significant difference (P>0.05). Conclusion: Used in heart failure patients with hypertension combined valsartan hydrochlorothiazide adjuvant therapy effect is remarkable, which can effectively improve the patients' heart function, Ang Ⅱ, NT - ProBNP and CTGF level. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
